Compounds > imatinib mesylate
Page last updated: 2024-09-03

imatinib mesylate and Ventricular Dysfunction, Left

imatinib mesylate has been researched along with Ventricular Dysfunction, Left in 11 studies

Research

Studies (11)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (45.45)29.6817
2010's5 (45.45)24.3611
2020's1 (9.09)2.80

Authors

AuthorsStudies
Aksu, S; Aladag, E; Buyukasik, Y; Demiroglu, H; Goker, H; Haznedaroglu, IC; Hekimsoy, V; Karakulak, UN; Kaya, EB; Ozcebe, O; Ozer, N; Sahiner, ML; Sayinalp, N1
Lee, SR; Yhim, HY1
Aries, A; Komati, H; Maharsy, W; Mansour, O; Nemer, M1
Campbell, P; Claggett, B; Querejeta Roca, G; Quinn, D; Shah, AM; Solomon, SD; Vazir, A1
Bosch, X; Garcia-Albeniz, X; Garcia-Alvarez, A; Loma-Osorio, P; Sionis, A; Sitges, M1
Ahluwalia, MS; Battiwalla, M; Cohen, IL; Francis, J; McCarthy, PL; Paplham, P; Smiley, S; Spangenthal, E; Wang, E; Wetzler, M1
Baxter, EJ; Cross, NC; Li, CY; Pardanani, A; Porrata, LF; Reeder, T; Tazelaar, HD; Tefferi, A; Witzig, TE1
Alroy, J; Beahm, C; Clubb, FJ; Durand, JB; Force, T; Grazette, L; Iliescu, C; Kerkelä, R; Patten, R; Pesant, S; Rosenzweig, A; Salomon, RN; Shevtsov, S; Van Etten, RA; Walters, B; Yacobi, R1
Mann, DL1
Strebhardt, K; Ullrich, A1
Blay, JY; Casali, PG; Issels, R; Judson, IR; Kotasek, D; Le Cesne, A; Reichard, P; Van Glabbeke, M; van Oosterom, AT; Verweij, J1

Trials

2 trial(s) available for imatinib mesylate and Ventricular Dysfunction, Left

ArticleYear
Impact of lowering pulmonary vascular resistance on right and left ventricular deformation in pulmonary arterial hypertension.
    European journal of heart failure, 2015, Volume: 17, Issue:1

    Topics: Adult; Benzamides; Female; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Treatment Outcome; Ultrasonography; Vascular Resistance; Ventricular Dysfunction, Left; Ventricular Dysfunction, Right

2015
Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: analysis of EORTC-ISG-AGITG study 62005.
    European journal of cancer (Oxford, England : 1990), 2007, Volume: 43, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Female; Gastrointestinal Stromal Tumors; Heart Failure; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Pyrimidines; Treatment Outcome; Ventricular Dysfunction, Left

2007

Other Studies

9 other study(ies) available for imatinib mesylate and Ventricular Dysfunction, Left

ArticleYear
Four-Dimensional Echocardiographic Evaluation of Left Ventricular Systolic Functions in Patients with Chronic Myeloid Leukaemia Receiving Tyrosine Kinase Inhibitors.
    Cardiovascular toxicology, 2021, Volume: 21, Issue:3

    Topics: Adult; Aged; Antineoplastic Agents; Cardiotoxicity; Cross-Sectional Studies; Dasatinib; Early Diagnosis; Echocardiography, Four-Dimensional; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Predictive Value of Tests; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Retrospective Studies; Risk Assessment; Systole; Time Factors; Treatment Outcome; Ventricular Dysfunction, Left; Ventricular Function, Left

2021
Rapid left ventricular thickening and thrombus caused by FIP1L1/PDGFRA-negative hypereosinophilic syndrome.
    Texas Heart Institute journal, 2013, Volume: 40, Issue:3

    Topics: Benzamides; Biopsy; Cerebral Infarction; Disease Progression; Echocardiography; Fibrosis; Genetic Predisposition to Disease; Hemodynamics; Humans; Hypereosinophilic Syndrome; Hypertrophy, Left Ventricular; Imatinib Mesylate; Magnetic Resonance Imaging; Male; Middle Aged; Phenotype; Piperazines; Platelet-Derived Growth Factor; Pyrimidines; Thrombosis; Time Factors; Treatment Outcome; Ventricular Dysfunction, Left; Ventricular Function, Left

2013
Ageing is a risk factor in imatinib mesylate cardiotoxicity.
    European journal of heart failure, 2014, Volume: 16, Issue:4

    Topics: Aging; Animals; bcl-X Protein; Benzamides; Cardiotoxicity; Echocardiography; GATA4 Transcription Factor; Imatinib Mesylate; In Situ Nick-End Labeling; Mice; Mice, Transgenic; Mitochondria, Heart; Myocytes, Cardiac; Oxidative Stress; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Rats; Risk Factors; Ventricular Dysfunction, Left

2014
Atypical cardiac manifestation of hypereosinophilic syndrome and reversible cardiotoxicity to imatinib.
    International journal of cardiology, 2010, Mar-04, Volume: 139, Issue:2

    Topics: Benzamides; Biopsy; Cardiotoxins; Echocardiography; Female; Heart Failure; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Magnetic Resonance Imaging; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thrombosis; Ventricular Dysfunction, Left

2010
Reversible cardiotoxicity with tyrosine kinase inhibitors.
    Clinical advances in hematology & oncology : H&O, 2010, Volume: 8, Issue:2

    Topics: Adult; Benzamides; Cardiotoxins; Central Nervous System Neoplasms; Dasatinib; Fatal Outcome; Female; Humans; Imatinib Mesylate; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Ventricular Dysfunction, Left

2010
Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders.
    Blood, 2003, May-01, Volume: 101, Issue:9

    Topics: Adult; Benzamides; Drug Evaluation; Enzyme Inhibitors; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Interleukin-5; Male; Middle Aged; Pilot Projects; Piperazines; Prospective Studies; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Remission Induction; Treatment Outcome; Ventricular Dysfunction, Left

2003
Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.
    Nature medicine, 2006, Volume: 12, Issue:8

    Topics: Adenosine Triphosphatases; Animals; Antineoplastic Agents; Benzamides; Calcium; Cell Death; Cell Membrane Permeability; Cells, Cultured; Cytochromes c; Dose-Response Relationship, Drug; Echocardiography; Heart Failure; Humans; Imatinib Mesylate; Injections, Intraperitoneal; Membrane Potentials; Mice; Mice, Inbred C57BL; Mitochondria, Heart; Mitochondrial Membranes; Myocytes, Cardiac; Piperazines; Pyrimidines; Sarcoplasmic Reticulum; Severity of Illness Index; Time Factors; Ventricular Dysfunction, Left

2006
Targeted cancer therapeutics: the heartbreak of success.
    Nature medicine, 2006, Volume: 12, Issue:8

    Topics: Antibodies, Monoclonal; Antineoplastic Agents; Benzamides; Drug Delivery Systems; Enzyme Inhibitors; Heart Failure; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Biological; Neoplasms; Piperazines; Pyrimidines; src-Family Kinases; Ventricular Dysfunction, Left

2006
Another look at imatinib mesylate.
    The New England journal of medicine, 2006, Dec-07, Volume: 355, Issue:23

    Topics: Animals; Antineoplastic Agents; Benzamides; Cell Death; Fusion Proteins, bcr-abl; Heart Failure; Humans; Imatinib Mesylate; Mice; Myocytes, Cardiac; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-abl; Pyrimidines; Sarcoplasmic Reticulum; Ventricular Dysfunction, Left

2006